{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:59:21Z","timestamp":1776214761190,"version":"3.50.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.det.2024.02.014","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T04:19:44Z","timestamp":1712204384000},"page":"429-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prevention of Psoriatic Arthritis"],"prefix":"10.1016","volume":"42","author":[{"given":"Alexander","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose U.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Prim"},{"issue":"10","key":"10.1016\/j.det.2024.02.014_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/art.39494","article-title":"The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study","volume":"68","author":"Eder","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.det.2024.02.014_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.det.2024.02.014_bib5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/bjd.13272","article-title":"Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis","volume":"171","author":"Langenbruch","year":"2014","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.014_bib6","doi-asserted-by":"crossref","first-page":"101692","DOI":"10.1016\/j.berh.2021.101692","article-title":"The epidemiology of psoriatic arthritis: A literature review","volume":"35","author":"Karmacharya","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin"},{"issue":"10","key":"10.1016\/j.det.2024.02.014_bib8","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/art.41741","article-title":"The epidemiology of psoriatic arthritis over five decades: a Population-Based study","volume":"73","author":"Karmacharya","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.det.2024.02.014_bib9","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1111\/jdv.13150","article-title":"Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey","volume":"29","author":"Van De Kerkhof","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jaad.2014.05.010","article-title":"Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European\/North American dermatology clinics","volume":"71","author":"Mease","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"10136","key":"10.1016\/j.det.2024.02.014_bib11","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Van den Bosch","year":"2018","journal-title":"Lancet"},{"issue":"10136","key":"10.1016\/j.det.2024.02.014_bib12","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41584-021-00578-2","article-title":"Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study","volume":"17","author":"Perez-Chada","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.det.2024.02.014_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.det.2024.02.014_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-019-0876-z","article-title":"Strategies to improve outcomes in psoriatic arthritis","volume":"21","author":"Ritchlin","year":"2019","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib17","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"issue":"Supplement_1","key":"10.1016\/j.det.2024.02.014_bib18","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2133.2011.10712.x","article-title":"Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy","volume":"166","author":"Hebert","year":"2012","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.014_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/ard.2008.089367","article-title":"Familial aggregation of psoriatic arthritis","volume":"68","author":"Chandran","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2024.02.014_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0640-3","article-title":"Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype","volume":"17","author":"FitzGerald","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib22","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1038\/ncomms7046","article-title":"Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib23","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1038\/s41467-018-06672-6","article-title":"Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients","volume":"9","author":"Patrick","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.det.2024.02.014_bib24","series-title":"A\u00a0meta-analysis of the relationship between tumor necrosis factor-\u03b1 polymorphisms and psoriasis","first-page":"39","author":"Wang","year":"2021"},{"key":"10.1016\/j.det.2024.02.014_bib25","first-page":"948723","article-title":"The protective role of HLA-DRB1 13 in autoimmune diseases","volume":"2015","author":"Bettencourt","year":"2015","journal-title":"J\u00a0immunol Res"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1136\/annrheumdis-2014-205461","article-title":"Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype","volume":"75","author":"Haroon","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.det.2024.02.014_bib27","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10067-013-2436-7","article-title":"Can traumatic injury trigger psoriatic arthritis? A review of the literature","volume":"33","author":"Hsieh","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/annrheumdis-2016-209334","article-title":"Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis","volume":"76","author":"Thorarensen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jaad.2020.08.060","article-title":"Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational studies","volume":"84","author":"Xie","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.014_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39259","article-title":"Microbiome in inflammatory arthritis and human rheumatic diseases","volume":"68","author":"Scher","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/art.38892","article-title":"Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","volume":"67","author":"Scher","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib33","doi-asserted-by":"crossref","first-page":"J314","DOI":"10.1016\/j.jaut.2009.12.001","article-title":"Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis","volume":"34","author":"Chandran","year":"2010","journal-title":"J\u00a0Autoimmun"},{"issue":"6","key":"10.1016\/j.det.2024.02.014_bib34","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/annrheumdis-2017-212681","article-title":"\u2018Deep Koebner\u2019phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis","volume":"77","author":"Tinazzi","year":"2018","journal-title":"Annals of the rheumatic diseases"},{"issue":"8","key":"10.1016\/j.det.2024.02.014_bib35","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1136\/annrheumdis-2011-201273","article-title":"Obesity and risk of incident psoriatic arthritis in US women","volume":"71","author":"Li","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatology and therapy"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","article-title":"Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management","volume":"52","author":"Russolillo","year":"2013","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.det.2024.02.014_bib39","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/annrheumdis-2013-204448","article-title":"Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.det.2024.02.014_bib40","doi-asserted-by":"crossref","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.det.2024.02.014_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-015-0540-1","article-title":"Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: a review of available evidence","volume":"17","author":"Ogdie","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib42","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjd.18227","article-title":"Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis","volume":"182","author":"Green","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2024.02.014_bib43","first-page":"152146","article-title":"Smoking and alcohol consumption are associated with peripheral musculoskeletal involvement in patients with spondyloarthritis (including psoriatic arthritis). Results from the ASAS-PerSpA study","volume":"Vol. 58","author":"Ladehesa-Pineda","year":"2023"},{"key":"10.1016\/j.det.2024.02.014_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-020-00891-x","article-title":"From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention","volume":"22","author":"Zabotti","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"10.1016\/j.det.2024.02.014_bib45","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s13555-023-01025-8","article-title":"Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database","volume":"13","author":"Merola","year":"2023","journal-title":"Dermatol Ther"},{"issue":"9","key":"10.1016\/j.det.2024.02.014_bib46","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3899\/jrheum.180796","article-title":"Psoriatic nail dystrophy is associated with erosive disease in the distal interphalangeal joints in psoriatic arthritis: a retrospective cohort study","volume":"46","author":"Antony","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.014_bib47","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/annrheumdis-2012-201617","article-title":"The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascular phenotype at insertions may play a role in arthritis development","volume":"72","author":"Aydin","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.det.2024.02.014_bib48","doi-asserted-by":"crossref","first-page":"e001067","DOI":"10.1136\/rmdopen-2019-001067","article-title":"Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia","volume":"5","author":"Zabotti","year":"2019","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib49","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.39973","article-title":"The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study","volume":"69","author":"Eder","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.014_bib50","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s13555-021-00663-0","article-title":"Development of a predictive model for screening patients with psoriasis at increased risk of psoriatic arthritis","volume":"2","author":"Wang","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2024.02.014_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/art.42661","article-title":"Derivation of a multivariable psoriatic arthritis risk estimation tool (PRESTO): a step towards prevention","author":"Eder","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.014_bib52","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.amjcard.2006.09.125","article-title":"The inflammation hypothesis and its potential relevance to statin therapy","volume":"99","author":"Forrester","year":"2007","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib53","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3899\/jrheum.210006","article-title":"Risk factors for diagnosis of psoriatic arthritis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis: a set of parallel case-control studies","volume":"49","author":"Meer","year":"2022","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.det.2024.02.014_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-017-0685-7","article-title":"The use of primary prevention statin therapy in those predisposed to atherosclerosis","volume":"19","author":"Garshick","year":"2017","journal-title":"Curr Atherosclerosis Rep"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.det.2024.02.014_bib56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/art.41946","article-title":"Incidence of psoriatic arthritis among patients receiving biologic treatments for psoriasis: a nested case\u2013control study","volume":"74","author":"Rosenthal","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib57","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.sapharm.2005.12.001","article-title":"Addressing the issue of channeling bias in observational studies with propensity scores analysis","volume":"2","author":"Lobo","year":"2006","journal-title":"Res Soc Adm Pharm"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib59","doi-asserted-by":"crossref","first-page":"AB1","DOI":"10.1016\/j.jaad.2023.07.016","article-title":"42744 Do Biologics for Psoriasis Prevent the Development of Psoriatic Arthritis? A population-based study","volume":"89","author":"Miao","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib60","doi-asserted-by":"crossref","first-page":"AB77","DOI":"10.1016\/j.jaad.2023.07.313","article-title":"43356 Protective Effects of Biologics against Psoriatic Arthritis in Patients with Psoriasis","volume":"89","author":"Shahsavari","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.014_bib61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40471-014-0027-z","article-title":"Misclassification in administrative claims data: quantifying the impact on treatment effect estimates","volume":"1","author":"Jonsson Funk","year":"2014","journal-title":"Current epidemiology reports"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib62","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/pds.4165","article-title":"Quantification of missing prescriptions in commercial claims databases: results of a cohort study","volume":"26","author":"Cepeda","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib63","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"The Lancet Rheumatology"},{"key":"10.1016\/j.det.2024.02.014_bib64","first-page":"FC08.8","article-title":"Optum database: analysis evaluating the risk of developing inflammatory arthritis in patients with psoriasis initiating treatment with biologics","author":"Strober","year":"2023","journal-title":"EADV"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib65","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib66","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/S2665-9913(23)00055-3","article-title":"Prevention of psoriatic arthritis: the next frontier","volume":"5","author":"Ogdie","year":"2023","journal-title":"The Lancet Rheumatology"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib67","first-page":"398","article-title":"Retrospective studies\u2013utility and caveats","volume":"50","author":"Talari","year":"2020","journal-title":"J\u00a0Roy Coll Phys Edinb"},{"key":"10.1016\/j.det.2024.02.014_bib68","doi-asserted-by":"crossref","first-page":"k1479","DOI":"10.1136\/bmj.k1479","article-title":"Biases in electronic health record data due to processes within the healthcare system: retrospective observational study","volume":"361","author":"Agniel","year":"2018","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib70","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2021.09.019","article-title":"Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: retrospective analysis of an electronic health records database in the United States","volume":"86","author":"Merola","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/annrheumdis-2012-202424","article-title":"Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study","volume":"73","author":"Ogdie","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"10.1016\/j.det.2024.02.014_bib72","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib73","first-page":"122","article-title":"Higher incidence rates of comorbidities in patients with psoriatic arthritis compared with the general population using US administrative claims data","volume":"25","author":"Kaine","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"7","key":"10.1016\/j.det.2024.02.014_bib74","first-page":"623","article-title":"Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database","volume":"24","author":"Walsh","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"6","key":"10.1016\/j.det.2024.02.014_bib75","first-page":"564","article-title":"Comorbidity and economic burden among moderate-to-severe psoriasis and\/or psoriatic arthritis patients in the US Department of Defense population","volume":"21","author":"Lee","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.det.2024.02.014_bib76","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1007\/s12325-022-02084-7","article-title":"Early real-world experience of tofacitinib for psoriatic arthritis: data from a United States healthcare claims database","volume":"39","author":"Mease","year":"2022","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.det.2024.02.014_bib77","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/aje\/152.3.197","article-title":"Choosing a retrospective design to assess joint genetic and environmental contributions to risk","volume":"152","author":"Weinberg","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.det.2024.02.014_bib78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0002-9343(80)90363-0","article-title":"The problem of \u201cprotopathic bias\u201d in case-control studies","volume":"68","author":"Horwitz","year":"1980","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib79","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/bcp.12705","article-title":"Indication bias or protopathic bias?","volume":"80","author":"Faillie","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib80","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/annrheumdis-2017-211625","article-title":"Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study","volume":"77","author":"Nguyen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib81","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/rheumatology\/keaa555","article-title":"Comment on: the impact of smoking on prevalence of psoriasis and psoriatic arthritis","volume":"60","author":"Dey","year":"2021","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.det.2024.02.014_bib82","doi-asserted-by":"crossref","first-page":"e063650","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.det.2024.02.014_bib83","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaad.2022.07.060","article-title":"Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry","volume":"87","author":"Ogdie","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.014_bib84","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pctr.0020018","article-title":"When and how can endpoints be changed after initiation of a randomized clinical trial","volume":"2","author":"Evans","year":"2007","journal-title":"PLoS clinical trials"},{"issue":"1","key":"10.1016\/j.det.2024.02.014_bib85","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2307\/2532599","article-title":"On the design and analysis of randomized clinical trials with multiple endpoints","volume":"49","author":"Tang","year":"1993","journal-title":"Biometrics"},{"key":"10.1016\/j.det.2024.02.014_bib86","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/annrheumdis-2021-220761","article-title":"Does biologic therapy impact the development of PsA among patients with psoriasis?","volume":"81","author":"Meer","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T21:40:00Z","timestamp":1716500400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0733863524000275"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.02.014","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of Psoriatic Arthritis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}